Assenagon Asset Management S.A. acquired a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 3,282 shares of the biotechnology company’s stock, valued at approximately $426,000.
Several other institutional investors have also added to or reduced their stakes in the stock. Ladenburg Thalmann Financial Services Inc. boosted its stake in United Therapeutics Corporation by 11.3% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 717 shares of the biotechnology company’s stock worth $104,000 after buying an additional 73 shares during the last quarter. Focused Wealth Management Inc boosted its stake in United Therapeutics Corporation by 17.5% in the first quarter. Focused Wealth Management Inc now owns 940 shares of the biotechnology company’s stock worth $127,000 after buying an additional 140 shares during the last quarter. Advisory Services Network LLC purchased a new stake in United Therapeutics Corporation during the first quarter worth approximately $147,000. Daiwa Securities Group Inc. boosted its stake in United Therapeutics Corporation by 17.4% in the first quarter. Daiwa Securities Group Inc. now owns 1,350 shares of the biotechnology company’s stock worth $183,000 after buying an additional 200 shares during the last quarter. Finally, Campbell & CO Investment Adviser LLC purchased a new stake in United Therapeutics Corporation during the first quarter worth approximately $204,000.
United Therapeutics Corporation (UTHR) traded down 1.298% during mid-day trading on Friday, hitting $129.655. 81,778 shares of the stock were exchanged. The company has a 50 day moving average price of $130.42 and a 200 day moving average price of $137.36. The firm has a market cap of $5.84 billion, a price-to-earnings ratio of 9.104 and a beta of 1.52. United Therapeutics Corporation has a 52-week low of $110.72 and a 52-week high of $169.89.
United Therapeutics Corporation (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, April 26th. The biotechnology company reported $3.89 earnings per share for the quarter, topping the consensus estimate of $3.12 by $0.77. The business had revenue of $370.50 million during the quarter, compared to the consensus estimate of $399.59 million. United Therapeutics Corporation had a net margin of 41.04% and a return on equity of 34.74%. The company’s revenue was up .4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.02 EPS. On average, analysts anticipate that United Therapeutics Corporation will post $14.44 EPS for the current year.
United Therapeutics Corporation announced that its board has approved a stock repurchase plan on Thursday, April 27th that allows the company to repurchase $250.00 million in shares. This repurchase authorization allows the biotechnology company to reacquire up to 4.6% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board of directors believes its shares are undervalued.
UTHR has been the subject of a number of research analyst reports. UBS AG initiated coverage on shares of United Therapeutics Corporation in a report on Wednesday, March 29th. They issued a “sell” rating and a $112.00 price target for the company. Credit Suisse Group reaffirmed an “underperform” rating and issued a $120.00 price target on shares of United Therapeutics Corporation in a report on Monday, April 3rd. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating on shares of United Therapeutics Corporation in a report on Monday, April 3rd. Cowen and Company cut shares of United Therapeutics Corporation from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $140.00 to $121.00 in a report on Monday, April 3rd. Finally, Wedbush reaffirmed an “outperform” rating and issued a $229.00 price target on shares of United Therapeutics Corporation in a report on Tuesday, April 4th. Five analysts have rated the stock with a sell rating, eight have issued a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $134.50.
In related news, Director Christopher Causey sold 590 shares of the company’s stock in a transaction on Thursday, July 6th. The shares were sold at an average price of $132.61, for a total value of $78,239.90. Following the completion of the sale, the director now owns 3,875 shares in the company, valued at approximately $513,863.75. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 1,234 shares of the company’s stock in a transaction on Thursday, June 22nd. The shares were sold at an average price of $132.32, for a total transaction of $163,282.88. Following the completion of the sale, the chief executive officer now owns 1,374 shares of the company’s stock, valued at approximately $181,807.68. The disclosure for this sale can be found here. Insiders have sold a total of 22,547 shares of company stock valued at $2,886,839 in the last 90 days. Insiders own 7.80% of the company’s stock.
About United Therapeutics Corporation
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.